In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow, as far as patient advocacy groups were concerned.
Not anymore.
On one hand, a new survey found, 60% of patient groups believed brand-name drugmakers maintained an “excellent” or “good” corporate reputation in 2022, which was up ever-so-slightly from 59% the year before. This was the best showing since the survey was launched in 2011 by PatientView, a research firm that canvassed 2,207 patient groups from 90 countries between November 2022 and February 2023.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
